Geke A.P. Hospers

24.8k total citations · 2 hit papers
282 papers, 7.4k citations indexed

About

Geke A.P. Hospers is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Geke A.P. Hospers has authored 282 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Oncology, 88 papers in Molecular Biology and 69 papers in Surgery. Recurrent topics in Geke A.P. Hospers's work include Cancer Immunotherapy and Biomarkers (53 papers), Cutaneous Melanoma Detection and Management (44 papers) and Melanoma and MAPK Pathways (43 papers). Geke A.P. Hospers is often cited by papers focused on Cancer Immunotherapy and Biomarkers (53 papers), Cutaneous Melanoma Detection and Management (44 papers) and Melanoma and MAPK Pathways (43 papers). Geke A.P. Hospers collaborates with scholars based in Netherlands, United States and Germany. Geke A.P. Hospers's co-authors include Elisabeth G.E. de Vries, Nanno H. Mulder, Erik F. J. de Vries, Coby Meijer, Yoka H. Kusumanto, Andor W.J.M. Glaudemans, Michel van Kruchten, Wendy Dam, Diane Bouïs and Boudewijn van Etten and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Geke A.P. Hospers

270 papers receiving 7.3k citations

Hit Papers

Locoregional Failure During and After Short-course Radiot... 2023 2026 2024 2025 2023 2025 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery
    2023 149 citations Esmée A. Dijkstra, Per J. Nilsson et al. Annals of Surgery profile →
  2. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2025 21 citations Geke A.P. Hospers et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geke A.P. Hospers Netherlands 45 3.9k 2.1k 1.7k 1.5k 1.4k 282 7.4k
Francesco Cognetti Italy 46 5.0k 1.3× 2.4k 1.1× 826 0.5× 2.3k 1.6× 1.0k 0.7× 221 8.5k
Sylvie Rottey Belgium 39 4.1k 1.1× 2.2k 1.0× 1.6k 1.0× 3.1k 2.1× 827 0.6× 236 7.9k
Louis Lacombe Canada 39 3.4k 0.9× 1.6k 0.8× 2.7k 1.6× 3.0k 2.0× 1.1k 0.8× 179 7.2k
Emilio Bria Italy 46 4.0k 1.0× 1.8k 0.8× 953 0.6× 2.8k 1.9× 523 0.4× 392 7.1k
Fumihiro Tanaka Japan 48 3.8k 1.0× 2.3k 1.1× 1.3k 0.7× 4.4k 3.0× 765 0.5× 404 8.7k
Roberto Bianco Italy 49 5.0k 1.3× 3.7k 1.7× 855 0.5× 3.4k 2.3× 898 0.6× 208 8.9k
Zhengjia Chen United States 51 3.1k 0.8× 2.4k 1.1× 1.2k 0.7× 2.5k 1.7× 669 0.5× 267 8.3k
William G. Cance United States 55 2.9k 0.7× 4.2k 2.0× 807 0.5× 940 0.6× 787 0.6× 174 9.2k
Michele Orditura Italy 44 3.4k 0.9× 1.9k 0.9× 1.2k 0.7× 2.1k 1.4× 413 0.3× 181 6.1k
Sandro Pignata Italy 51 4.4k 1.1× 2.4k 1.2× 2.4k 1.4× 1.5k 1.0× 426 0.3× 434 10.6k

Countries citing papers authored by Geke A.P. Hospers

Since Specialization
Citations

This map shows the geographic impact of Geke A.P. Hospers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geke A.P. Hospers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geke A.P. Hospers more than expected).

Fields of papers citing papers by Geke A.P. Hospers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geke A.P. Hospers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geke A.P. Hospers. The network helps show where Geke A.P. Hospers may publish in the future.

Co-authorship network of co-authors of Geke A.P. Hospers

This figure shows the co-authorship network connecting the top 25 collaborators of Geke A.P. Hospers. A scholar is included among the top collaborators of Geke A.P. Hospers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geke A.P. Hospers. Geke A.P. Hospers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bloem, Martin W., Karijn P.M. Suijkerbuijk, Franchette W.P.J. van den Berkmortel, et al.. (2025). Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry. European Journal of Cancer. 223. 115514–115514.
2.
Groot, Saskia de, Hedwig M. Blommestein, B Leeneman, et al.. (2025). Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma. Medical Decision Making. 45(3). 302–317.
3.
Hiel, Bernies van der, Berlinda J. de Wit–van der Veen, Wouter V. Vogel, et al.. (2025). Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma. EJNMMI Research. 15(1). 60–60.
4.
Berkmortel, Franchette van den, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, et al.. (2024). Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. European Journal of Cancer. 208. 114190–114190. 3 indexed citations
5.
Eertwegh, Alfons J.M. van den, John B.A.G. Haanen, Rozemarijn S. van Rijn, et al.. (2024). BRAF/MEK inhibitor rechallenge in advanced melanoma patients. Cancer. 130(9). 1673–1683. 5 indexed citations
6.
Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660. 2 indexed citations
7.
Dijkstra, Esmée A., Per J. Nilsson, Geke A.P. Hospers, et al.. (2023). Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery. Annals of Surgery. 278(4). e766–e772. 149 indexed citations breakdown →
8.
Zeijl, Michiel C.T. van, Liesbeth C. de Wreede, Michel W.J.M. Wouters, et al.. (2023). Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands. Journal of Immunotherapy. 46(5). 197–204. 8 indexed citations
9.
Reijers, Irene L. M., Alexander M. Menzies, Judith M. Versluis, et al.. (2023). The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.. Journal of Clinical Oncology. 41(16_suppl). 101–101. 6 indexed citations
10.
Eertwegh, Alfonsus Johannes Maria van den, Liesbeth C. de Wreede, Doranne L. Hilarius, et al.. (2021). Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers. 13(20). 5077–5077. 2 indexed citations
11.
Donk, Pim P. van de, Thijs T. Wind, Elly L. van der Veen, et al.. (2021). Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. European Journal of Nuclear Medicine and Molecular Imaging. 48(13). 4369–4376. 35 indexed citations
12.
Leeneman, B, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, et al.. (2020). Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers. 12(4). 1003–1003. 12 indexed citations
13.
Wind, Thijs T., Ranko Gaćeša, Arnau Vich Vila, et al.. (2020). Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Research. 30(3). 235–246. 44 indexed citations
14.
Kooij, Monique K. van der, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, et al.. (2020). Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers. 12(8). 2072–2072. 32 indexed citations
15.
16.
Kruchten, Michel van, Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, et al.. (2014). Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer. Cancer Discovery. 5(1). 72–81. 158 indexed citations
17.
Nagengast, Wouter B., Marjolijn N. Lub–de Hooge, Sjoukje F. Oosting, et al.. (2010). VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. Cancer Research. 71(1). 143–153. 83 indexed citations
18.
Hooge, Marjolijn N. Lub–de, Adrienne H. Brouwers, Johan R. de Jong, et al.. (2010). VEGF-SPECT with In-111-bevacizumab in stage III/IV melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging. 37. 1 indexed citations
19.
Munnink, Thijs H. Oude, Wouter B. Nagengast, Adrienne H. Brouwers, et al.. (2009). Molecular imaging of breast cancer. The Breast. 18. S66–S73. 74 indexed citations
20.
Mulder, Nanno H., Wim J. Sluiter, Coby Meijer, et al.. (2005). Influence of p53 Status on the HSV-Tk/GCV-Induced Bystander Effect in a Panel of Human Ovarian Carcinoma Cell Lines. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 15(3). 151–159. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Cognetti Breakdown of academic impact, for papers by Sylvie Rottey Breakdown of academic impact, for papers by Louis Lacombe Breakdown of academic impact, for papers by Emilio Bria Breakdown of academic impact, for papers by Fumihiro Tanaka Breakdown of academic impact, for papers by Roberto Bianco Breakdown of academic impact, for papers by Zhengjia Chen Breakdown of academic impact, for papers by William G. Cance Breakdown of academic impact, for papers by Michele Orditura Breakdown of academic impact, for papers by Sandro Pignata
Rankless by CCL
2026